Product How it works Pricing Blog FAQ About Contact
Protalix Biotherapeutics

Protalix Biotherapeutics (NYSE: PLX) net income

Protalix Biotherapeutics reported a net loss of $6.6m for fiscal 2025; in fiscal 2024 it reported a net profit of $2.9m. Earnings per share were −$0.08.

Protalix Biotherapeutics's net income has fallen for 2 years in a row, and its best year of the last 10 was fiscal 2023. The biggest drop was in fiscal 2024, −64.7%. It reported a loss in 8 of those 10 years.

Net income, in millions of US dollars-29.42016-83.42017-26.52018-18.32019-6.52020-27.62021-14.920228.320232.92024-6.62025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Net income by fiscal year

Fiscal yearNet incomeChangeNet marginEarnings per share
2025−$6.6m−325.2%−12.5%−$0.08
2024$2.9m−64.7%5.5%$0.04
2023$8.3m—12.7%$0.12
2022−$14.9m—−31.3%−$0.31
2021−$27.6m—−71.9%−$0.62
2020−$6.5m—−10.4%−$0.22
2019−$18.3m—−33.4%−$1.23
2018−$26.5m—−77.3%—
2017−$83.4m—−395.9%—
2016−$29.4m—−319.2%—

The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Protalix Biotherapeutics net income compared with its sector

By net income for its latest fiscal year, Protalix Biotherapeutics ranks 185th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Protalix Biotherapeutics, −12.5%.

RankCompanyNet incomeNet margin
183rdAkebia Therapeutics−$5.3m−2.3%
184thAssembly Biosciences−$6.1m−8.5%
185thProtalix Biotherapeutics−$6.6m−12.5%
186thStoke Therapeutics−$6.9m−3.7%
187thNeogen−$7.9m−0.9%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the net income of Protalix Biotherapeutics

How much did Protalix Biotherapeutics earn in fiscal 2025?
Protalix Biotherapeutics reported a net loss of $6.6m for fiscal 2025. In fiscal 2024 it reported a net profit of $2.9m.
What are the earnings per share of Protalix Biotherapeutics?
They were −$0.08 in fiscal 2025, compared with $0.04 in fiscal 2024.
What was the most profitable year for Protalix Biotherapeutics?
Of its last 10 fiscal years, fiscal 2023, with $8.3m.
Where does Protalix Biotherapeutics rank in its sector by net income?
It ranks 185th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
Where do the figures for Protalix Biotherapeutics come from?
From the annual report (Form 10-K) that Protalix Biotherapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Protalix Biotherapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Protalix Biotherapeutics: the Protalix Biotherapeutics page · annual accounts · revenue · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.